[Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
Identifieur interne : 001163 ( PubMed/Curation ); précédent : 001162; suivant : 001164[Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
Auteurs : M. Bailbé ; S. Karolewicz ; J Ph Neau ; P. Dumas ; R. GilSource :
- Revue neurologique [ 0035-3787 ] ; 2002.
Descripteurs français
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Delusions (epidemiology), Delusions (etiology), Female, France (epidemiology), Hallucinations (epidemiology), Hallucinations (etiology), Health Surveys, Humans, Inpatients (psychology), Levodopa (therapeutic use), Male, Middle Aged, Outpatients (psychology), Paranoid Disorders (epidemiology), Paranoid Disorders (etiology), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (psychology), Severity of Illness Index, Sleep Wake Disorders (epidemiology), Sleep Wake Disorders (etiology).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- geographic , epidemiology : France.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease.
- epidemiology : Delusions, Hallucinations, Paranoid Disorders, Parkinson Disease, Sleep Wake Disorders.
- etiology : Delusions, Hallucinations, Paranoid Disorders, Sleep Wake Disorders.
- psychology : Inpatients, Outpatients, Parkinson Disease.
- Aged, Aged, 80 and over, Female, Health Surveys, Humans, Male, Middle Aged, Severity of Illness Index.
Abstract
Parkinson's disease cannot be reduced to its motor symptoms. Psychological and behavioral disorders often accompany its development. Our study was conducted in June 1999 among 36 neurologists practicing in hospital or private clinic settings in the Poitou-Charentes area. Neurologists were requested to record hallucinations, delusions and nocturnal events observed in Parkinson's patients. A total of 152 reports were collected from 17 physicians. Fifty-three percent of the patients attended hospital clinics and 47p.100; were seen at the physician's office. Hallucinations were recorded in 23.1p.100; of the patients. The risk of hallucination symptoms was higher among patients seen at hospital clinics and who had more advanced disease. Only 7.2p.100; of the patients reported delusions, most often of a persecution type. Nocturnal events affected 49.3p.100; of the patients. The appearance of such symptoms was highly related to Hoehn and Yahr stage and was more frequent in hospital patients. Hallucinations, delusions, and nocturnal events affect patients with advanced Parkinson's disease, associated with long-term L-dopa treatment. Eighty-three percent of the patients had such symptoms and most of them used L-dopa. This long-term treatment is linked to these three symptoms. Hallucinations were increasingly reported for patients with increasing long-term medication with dopaminergic agonists. Nocturnal events, for patients on L-dopa, were associated with advanced disease, long-term treatment with L-dopa, and hospitalization. Psychic and behavioral disorders appear frequently in Parkinson's disease patients and are inter-related. Physicians should be aware of the relationship with treatment to avoid aggravation.
PubMed: 11965176
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001204
Links to Exploration step
pubmed:11965176Curation
No country items
M. Bailbé<affiliation><nlm:affiliation>Service de clinique neurologique, Hôpital Jean Bernard, CHU La Milétrie, 86021 Poitiers cedex.</nlm:affiliation><wicri:noCountry code="subField">86021 Poitiers cedex</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].</title><author><name sortKey="Bailbe, M" sort="Bailbe, M" uniqKey="Bailbe M" first="M" last="Bailbé">M. Bailbé</name><affiliation><nlm:affiliation>Service de clinique neurologique, Hôpital Jean Bernard, CHU La Milétrie, 86021 Poitiers cedex.</nlm:affiliation><wicri:noCountry code="subField">86021 Poitiers cedex</wicri:noCountry></affiliation></author><author><name sortKey="Karolewicz, S" sort="Karolewicz, S" uniqKey="Karolewicz S" first="S" last="Karolewicz">S. Karolewicz</name></author><author><name sortKey="Neau, J Ph" sort="Neau, J Ph" uniqKey="Neau J" first="J Ph" last="Neau">J Ph Neau</name></author><author><name sortKey="Dumas, P" sort="Dumas, P" uniqKey="Dumas P" first="P" last="Dumas">P. Dumas</name></author><author><name sortKey="Gil, R" sort="Gil, R" uniqKey="Gil R" first="R" last="Gil">R. Gil</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:11965176</idno><idno type="pmid">11965176</idno><idno type="wicri:Area/PubMed/Corpus">001204</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001204</idno><idno type="wicri:Area/PubMed/Curation">001163</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001163</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].</title><author><name sortKey="Bailbe, M" sort="Bailbe, M" uniqKey="Bailbe M" first="M" last="Bailbé">M. Bailbé</name><affiliation><nlm:affiliation>Service de clinique neurologique, Hôpital Jean Bernard, CHU La Milétrie, 86021 Poitiers cedex.</nlm:affiliation><wicri:noCountry code="subField">86021 Poitiers cedex</wicri:noCountry></affiliation></author><author><name sortKey="Karolewicz, S" sort="Karolewicz, S" uniqKey="Karolewicz S" first="S" last="Karolewicz">S. Karolewicz</name></author><author><name sortKey="Neau, J Ph" sort="Neau, J Ph" uniqKey="Neau J" first="J Ph" last="Neau">J Ph Neau</name></author><author><name sortKey="Dumas, P" sort="Dumas, P" uniqKey="Dumas P" first="P" last="Dumas">P. Dumas</name></author><author><name sortKey="Gil, R" sort="Gil, R" uniqKey="Gil R" first="R" last="Gil">R. Gil</name></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Delusions (epidemiology)</term><term>Delusions (etiology)</term><term>Female</term><term>France (epidemiology)</term><term>Hallucinations (epidemiology)</term><term>Hallucinations (etiology)</term><term>Health Surveys</term><term>Humans</term><term>Inpatients (psychology)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Outpatients (psychology)</term><term>Paranoid Disorders (epidemiology)</term><term>Paranoid Disorders (etiology)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (psychology)</term><term>Severity of Illness Index</term><term>Sleep Wake Disorders (epidemiology)</term><term>Sleep Wake Disorders (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Delusions</term><term>Hallucinations</term><term>Paranoid Disorders</term><term>Parkinson Disease</term><term>Sleep Wake Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Delusions</term><term>Hallucinations</term><term>Paranoid Disorders</term><term>Sleep Wake Disorders</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Inpatients</term><term>Outpatients</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Health Surveys</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease cannot be reduced to its motor symptoms. Psychological and behavioral disorders often accompany its development. Our study was conducted in June 1999 among 36 neurologists practicing in hospital or private clinic settings in the Poitou-Charentes area. Neurologists were requested to record hallucinations, delusions and nocturnal events observed in Parkinson's patients. A total of 152 reports were collected from 17 physicians. Fifty-three percent of the patients attended hospital clinics and 47p.100; were seen at the physician's office. Hallucinations were recorded in 23.1p.100; of the patients. The risk of hallucination symptoms was higher among patients seen at hospital clinics and who had more advanced disease. Only 7.2p.100; of the patients reported delusions, most often of a persecution type. Nocturnal events affected 49.3p.100; of the patients. The appearance of such symptoms was highly related to Hoehn and Yahr stage and was more frequent in hospital patients. Hallucinations, delusions, and nocturnal events affect patients with advanced Parkinson's disease, associated with long-term L-dopa treatment. Eighty-three percent of the patients had such symptoms and most of them used L-dopa. This long-term treatment is linked to these three symptoms. Hallucinations were increasingly reported for patients with increasing long-term medication with dopaminergic agonists. Nocturnal events, for patients on L-dopa, were associated with advanced disease, long-term treatment with L-dopa, and hospitalization. Psychic and behavioral disorders appear frequently in Parkinson's disease patients and are inter-related. Physicians should be aware of the relationship with treatment to avoid aggravation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11965176</PMID><DateCreated><Year>2002</Year><Month>04</Month><Day>19</Day></DateCreated><DateCompleted><Year>2002</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Print"><Volume>158</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].</ArticleTitle><Pagination><MedlinePgn>203-10</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease cannot be reduced to its motor symptoms. Psychological and behavioral disorders often accompany its development. Our study was conducted in June 1999 among 36 neurologists practicing in hospital or private clinic settings in the Poitou-Charentes area. Neurologists were requested to record hallucinations, delusions and nocturnal events observed in Parkinson's patients. A total of 152 reports were collected from 17 physicians. Fifty-three percent of the patients attended hospital clinics and 47p.100; were seen at the physician's office. Hallucinations were recorded in 23.1p.100; of the patients. The risk of hallucination symptoms was higher among patients seen at hospital clinics and who had more advanced disease. Only 7.2p.100; of the patients reported delusions, most often of a persecution type. Nocturnal events affected 49.3p.100; of the patients. The appearance of such symptoms was highly related to Hoehn and Yahr stage and was more frequent in hospital patients. Hallucinations, delusions, and nocturnal events affect patients with advanced Parkinson's disease, associated with long-term L-dopa treatment. Eighty-three percent of the patients had such symptoms and most of them used L-dopa. This long-term treatment is linked to these three symptoms. Hallucinations were increasingly reported for patients with increasing long-term medication with dopaminergic agonists. Nocturnal events, for patients on L-dopa, were associated with advanced disease, long-term treatment with L-dopa, and hospitalization. Psychic and behavioral disorders appear frequently in Parkinson's disease patients and are inter-related. Physicians should be aware of the relationship with treatment to avoid aggravation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bailbé</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de clinique neurologique, Hôpital Jean Bernard, CHU La Milétrie, 86021 Poitiers cedex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karolewicz</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Neau</LastName><ForeName>J Ph</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Dumas</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><CollectiveName>Association des neurologues du Poitou-Charentes</CollectiveName></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><VernacularTitle>Hallucinations, idées délirantes, événements nocturnes chez 152 patients atteints de maladie de Parkinson. Enquête régionale.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11965176</ArticleId><ArticleId IdType="pii">MDOI-RN-02-2002-158-2-0035-3787-101019-ART7</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001163 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001163 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:11965176
|texte= [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:11965176" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |